Sermorelin vs Tesamorelin: What’s the Difference?
The main difference between Sermorelin and Tesamorelin is mechanism: Sermorelin is studied for endogenous gh-release research — Classic GHRH analog (29 amino acids). Tesamorelin is studied for visceral fat reduction research — Stabilized GHRH analog.
Original GHRH 1-29 vs stabilized GHRH analog.
Key differences between Sermorelin and Tesamorelin
- •Mechanism: Sermorelin — Classic GHRH analog (29 amino acids). Tesamorelin — Stabilized GHRH analog.
- •Primary research focus: Sermorelin is studied for endogenous gh-release research; Tesamorelin is studied for visceral fat reduction research.
- •Depth of human research: Sermorelin — Moderate; Tesamorelin — Strong.
- •Typical study cadence cited in the literature: Sermorelin — Daily before bed (commonly 5 nights on, 2 off); Tesamorelin — Daily, typically evening.
| Attribute | Sermorelin GHRH(1-29) | Tesamorelin Stabilized GHRH analog |
|---|---|---|
| Category | Muscle Growth & Performance | Muscle Growth & Performance |
| Best known for | Endogenous GH-release research | Visceral fat reduction research |
| Mechanism of action | Classic GHRH analog (29 amino acids). Mild, well-tolerated GH release. | Stabilized GHRH analog. Notably effective at reducing visceral (abdominal) fat. |
| Human research | Moderate | Strong |
| Animal research | Moderate | Moderate |
| Mechanistic research | Established | Established |
| Study cadence cited | Daily before bed (commonly 5 nights on, 2 off) | Daily, typically evening |
| In plain English | The original GH peptide. Sermorelin is shorter-acting and milder than CJC-1295 — researchers consider it the gentle introduction to GH peptide research. | Tesamorelin is the GH peptide with the strongest data for shrinking visceral (belly) fat specifically. |
| How it works | Stimulates pituitary GH release by binding the GHRH receptor. | Activates GHRH receptors, increasing GH and IGF-1 with documented preferential effects on visceral adipose tissue. |
| Researchers study | Age-related GH decline, body composition, sleep, and pediatric GH deficiency. | Visceral fat reduction, lipid metabolism, and cognitive function in older adults. |
| Internet discussion | Older audience favors it for being well-studied with a long history. | Discussed by people specifically targeting belly fat. |
Mechanism and research evidence, side by side
How Sermorelin and Tesamorelin differ at the receptor level, and how much published research currently supports each. Evidence ratings describe the depth of publicly available literature — they are not claims of safety or effectiveness.
Sermorelin
Classic GHRH analog (29 amino acids). Mild, well-tolerated GH release.
- GHRH and/or ghrelin receptors in the pituitary
- Pulsatile growth hormone release
- Downstream IGF-1, body-composition and recovery endpoints
- Human research
- Moderate
- Animal research
- Moderate
- Mechanistic research
- Established
Anti-aging, sleep quality, recovery, mild GH support
Tesamorelin
Stabilized GHRH analog. Notably effective at reducing visceral (abdominal) fat.
- GHRH and/or ghrelin receptors in the pituitary
- Pulsatile growth hormone release
- Downstream IGF-1, body-composition and recovery endpoints
- Human research
- Strong
- Animal research
- Moderate
- Mechanistic research
- Established
Visceral fat reduction (particularly abdominal), GH/IGF-1 increase
Sermorelin
Endogenous GH-release research
The original GH peptide. Sermorelin is shorter-acting and milder than CJC-1295 — researchers consider it the gentle introduction to GH peptide research.
Stimulates pituitary GH release by binding the GHRH receptor.
Age-related GH decline, body composition, sleep, and pediatric GH deficiency.
Older audience favors it for being well-studied with a long history.
Sermorelin is the original GHRH analog with the longest research history in GH peptide work.
Tesamorelin
Visceral fat reduction research
Tesamorelin is the GH peptide with the strongest data for shrinking visceral (belly) fat specifically.
Activates GHRH receptors, increasing GH and IGF-1 with documented preferential effects on visceral adipose tissue.
Visceral fat reduction, lipid metabolism, and cognitive function in older adults.
Discussed by people specifically targeting belly fat.
Tesamorelin is the GHRH analog with strongest data for reducing visceral fat specifically.